阿托伐他汀联合人脐带间充质干细胞移植治疗猪急性心肌梗死的研究  

Atorvastatin combined with human umbilical cord mesenchymal stem cells transplantation for the treatment of acute myocardial infarction in swines

作　　者：裴宇[1] 梁振兴[1] 郝爽 张竞超[1] 徐敬[1] Pei Yu;Liang Zhenxing;Hao Shuang;Zhang Jingchao;Xu Jing(Department of Cardiovascular Surgery,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院心血管外科,450052

出　　处：《中华实验外科杂志》2021年第11期2191-2194,共4页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(81700236)。

摘　　要：目的观察阿托伐他汀联合人脐带间充质干细胞移植治疗猪急性心肌梗死的疗效。方法采集人脐带,分离、培养、扩增间充质干细胞至第6代,氯甲基苯甲酰胺(CM-Dil)免疫荧光标记。结扎冠脉前降支制作猪急性心肌梗死模型,18头猪随机分为对照组(Control)(n=6)、干细胞组(MSCs)(n=6)及阿托伐他汀联合干细胞组(ATV+MSCs)(n=6)。MSCs移植后48 h两移植组各处死2头猪,免疫荧光染色观察MSCs存活率。术后1 d及术后6周分别进行超声、核素心肌灌注显像检查。术后6周取标本进行Masson三色法染色和vWF免疫组织化学染色。采用One-way ANOVA、LSD等分析。结果移植后ATV+MSCs组MSCs存活率[(223.8±28.5)个/高倍视野]显著大于MSCs组[(153.5±21.0)个/高倍视野,F=15.743,P<0.01]。术后6周ATV+MSCs组左室射血分数[(59.3±2.6)%]显著高于Control组[(52.2±1.5)%,t=4.011,P<0.05]。术后6周ATV+MSCs组[(12.0±1.0)%]和MSCs组[(12.7±2.5)%]静息放射核素心肌灌注质量缺损百分率显著低于Control组[(17.7±0.6)%,t=4.341、3.831,P<0.01]。Masson三色法染色ATV+MSCs组纤维组织面积百分比[(14.0±2.4)%]显著低于MSCs组[(19.3±1.6)%,t=2.667,P<0.05]。vWF免疫组织化学染色ATV+MSCs组vWF阳性累计吸光度(A)值[(8 100.8±1 068.9)像素/高倍视野]显著高于MSCs组[(3 958.6±1 038.8)像素/高倍视野,t=6.921,P<0.01]。结论阿托伐他汀联合人脐带MSCs移植治疗猪心肌梗死,能增加移植MSCs存活率,减少瘢痕组织形成,增加毛细血管生成,改善心功能,增强MSCs移植疗效。Objective To observe the efficacy of atorvastatin combined with human umbilical cord mesenchymal stem cells transplantation in the treatment of swine acute myocardial infarction.Methods Human umbilical cord was collected,and the MSCs were isolated,cultured and expanded to the 6th generation,and labeled with CM-Dil immunofluorescence.Acute myocardial infarction model was made by ligating the anterior descending coronary artery of the swine.18 swines were randomly divided into control group(Control)(n=6),mesenchymal stem cells group(MSCs)(n=6),and atorvastatin and mesenchymal stem cells group(ATV+MSCs)(n=6).48 hours after transplantation,two swines of each transplantation group were sacrificed,and the survival rate of MSCs was observed.Echocardiography and Single-Photon Emission Computed Tomography were performed on the 1st day and 6 weeks after the operation.6 weeks after surgery,and specimens were taken for Masson trichrome staining and vWF immunohistochemical staining.Statistical methods use one-way ANOVA,LSD,et al.Results The survival rate of MSCs in ATV+MSCs group[(223.8±28.5)cells/hpf]was significantly higher than that of MSCs group[(153.5±21.0)cells/hpf,F=15.743,P<0.01].6 weeks after surgery,the left ventricular ejection fraction of the ATV+MSCs group[(59.3±2.6)%]was significantly higher than that of the Control group[(52.2±1.5)%,t=4.011,P<0.05].6 weeks after surgery,SPECT showed that the myocardial perfusion mass defects percentage of the ATV+MSCs group[(12.0±1.0)%]and the MSCs group[(12.7±2.5)%]was significantly lower than that of the Control group(t=4.341,3.831,P<0.01).The percentage of fibrous tissue area of ATV+MSCs group[(14.0±2.4)%]was significantly lower than that of MSCs group[(19.3±1.6)%,t=2.667,P<0.05].In ATV+MSCs group the vWF positive integrated absorbance[(8100.8±1068.9)pixels/hpf]was significantly higher than that in MSCs group[(3958.6±1038.8)pixels/hpf,t=6.921,P<0.01].Conclusion ATV combined with human umbilical cord MSCs transplantation can increase the survival rate of MSCs,reduce

关 键 词：急性心肌梗死 脐带间充质干细胞 阿托伐他汀 移植 

分 类 号：R542.22[医药卫生—心血管疾病]